Stocks › RGEN

REPLIGEN CORP

RGEN·Nasdaq·United States United States·USD
$163.81
-6.48 (-3.81%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
RGEN
REPLIGEN CORP · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RGENS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of RGEN by members of U.S. Congress · 8 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Lisa C. McClainLisa C. McClainHouse · R · MI RGENREPLIGEN CORP · Stock Sale
$1,001 - $15,000
Nov 21, 2025 Oct 31, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI RGENREPLIGEN CORP · Stock Sale
$1,001 - $15,000
Nov 21, 2025 Oct 30, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI RGENREPLIGEN CORP · Stock Purchase
$1,001 - $15,000
Nov 21, 2025 Oct 30, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI RGENREPLIGEN CORP · Stock Sale
$1,001 - $15,000
Aug 13, 2025 Jun 17, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI RGENREPLIGEN CORP · Stock Purchase
$1,001 - $15,000
Aug 13, 2025 Jul 22, 2025 Filing ↗
Lisa C. McClainLisa C. McClainHouse · R · MI RGENREPLIGEN CORP · Stock Purchase
$1,001 - $15,000
Aug 13, 2025 Jun 11, 2025 Filing ↗
Jefferson ShreveJefferson ShreveHouse · R · IN RGENREPLIGEN CORP · Stock Sale
$15,001 - $50,000
May 8, 2025 Apr 7, 2025 Filing ↗
Ro KhannaRo KhannaHouse · D · CA RGENREPLIGEN CORP · Common Stock Sale
$1,001 - $15,000
Jan 7, 2022 Dec 14, 2021 Filing ↗

Whale Activity

Position changes in RGEN reported for 2026-09-30 by 575 institutional filers
Increased: 186New: 100Held: 79Decreased: 136Closed: 50No prior filing: 24
  • Increased186
  • New100
  • Held79
  • Decreased136
  • Closed50
  • No prior filing24
FilerSharesValueChange
FMR LLC7.4M$1.41Bincreased
BlackRock, Inc.5.7M$1.10Bincreased
UNITED CAPITAL FINANCIAL ADVISORS, LLC2.8M$536.3Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC2.4M$469.6Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC2.3M$436.7Mdecreased
Invesco Ltd.2.1M$410.2Mincreased
MASSACHUSETTS FINANCIAL SERVICES CO /MA/2.0M$392.3Mincreased
PRICE T ROWE ASSOCIATES INC /MD/2.0M$390.3Mincreased
STATE STREET CORP1.8M$355.5Mincreased
AMERIPRISE FINANCIAL INC1.7M$324.7M—
MAVERICK CAPITAL LTD1.4M$272.5Mdecreased
T. Rowe Price Investment Management, Inc.1.4M$268.6Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by RGEN insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: -26.5K2025 Q12025 Q2: -26.4K2025 Q22025 Q3: -27.3K2025 Q32025 Q4: -54.5K2025 Q42026 Q1: 02026 Q12026 Q2: -4,5652026 Q22026 Q3: -27.4K2026 Q32026 Q4: -5,5352026 Q4

Recent Insider Transactions

1,099 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Loeillot OlivierChief Executive Officer · Director Sale −4,202 $190.00 $798K Oct 5, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Sale −1,333 $178.75 $238K Oct 5, 2026 Form 4 ↗
Garland Jason KCFO Tax withholding −421 $189.68 $80K Sep 25, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Sale −4,542 $190.00 $863K Sep 24, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Option exercise +4,542 $155.38 $706K Sep 24, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Sale −8,404 $190.00 $1.6M Sep 24, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Option exercise +8,404 $154.96 $1.3M Sep 24, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Sale −5,426 $180.00 $977K Sep 21, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Option exercise +5,426 $141.79 $769K Sep 21, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Sale −3,035 $165.90 $504K Sep 4, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Tax withholding −2,842 $169.61 $482K Sep 3, 2026 Form 4 ↗
Hughes ViolettaCHIEF ACCOUNTING OFFICER Tax withholding −277 $170.02 $47K Sep 1, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Sale −5,426 $180.00 $977K Aug 20, 2026 Form 4 ↗
Loeillot OlivierChief Executive Officer · Director Option exercise +5,426 $141.79 $769K Aug 20, 2026 Form 4 ↗
Garland Jason KCFO Sale −530 $150.00 $80K Jul 16, 2026 Form 4 ↗
Garland Jason KCFO Sale −733 $145.00 $106K Jun 25, 2026 Form 4 ↗
Konstantinov KonstantinDirector Grant / award +995 $0.00 $0 May 14, 2026 Form 4 ↗
Madaus Martin DDirector Grant / award +995 $0.00 $0 May 14, 2026 Form 4 ↗
EGLINTON MANNER CARRIEDirector Grant / award +995 $0.00 $0 May 14, 2026 Form 4 ↗
MUIR GLENN PDirector Grant / award +995 $0.00 $0 May 14, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding RGEN · SEC Form N-PORT
FundSharesValue% of fundAs of
iShares Core S&P Mid-Cap ETF
iShares Trust
1.8M$247.6M0.20%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.7M$232.3M0.01%Jun 30, 2026
MFS Mid Cap Growth Fund
MFS Series Trust IV
1.0M$189.0M1.46%Aug 31, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
1.2M$167.7M0.09%Jun 30, 2026
Invesco Discovery Fund
AIM Counselor Series Trust (Invesco Counselor Series Trust)
817.9K$148.0M2.00%Aug 31, 2026
T. Rowe Price New Horizons Fund, Inc.963.0K$131.4M0.89%Jun 30, 2026
Select Health Care Portfolio
Fidelity Select Portfolios
570.0K$103.2M1.53%Aug 31, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
709.0K$96.7M0.21%Jun 30, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund
Fidelity Rutland Square Trust II
515.3K$93.3M0.04%Aug 31, 2026
Select Medical Technology and Devices Portfolio
Fidelity Select Portfolios
500.0K$90.5M2.70%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list RGEN's shares (CUSIP 759916109), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 7.4M shares13.0%
    Oct 7, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 7.4M shares13.0%
    Oct 7, 2026 · ↗
  • T. Rowe Price Associates, Inc.SCHEDULE 13G/A · passive (13G) · 1.8M shares3.1%
    Aug 14, 2026 · ↗
  • Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 2.8M shares5.0%
    Jul 31, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming REPLIGEN CORP as client

No lobbying filings found naming REPLIGEN CORP as the client.

Government Contracts

Federal awards to repligen · USAspending
$204KAwarded · 2 contracts on record
  • Department of AgricultureFIRM-FIXED PRICE PURCHASE ORDER FOR A SOLOVPE PLUS.$169K
    Aug 29, 2026 · ↗
  • Department of Health and Human ServicesKR2I BASE SYSTEM TANGENTIAL FLOW FILTRATION (TFF)$34K
    Sep 16, 2024 · ↗

U.S. Patents

Recent USPTO applications naming REPLIGEN CORP

No USPTO patent applications found for REPLIGEN CORP.

Annual Financials

From RGEN's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Operating income$55.2M-$35.1M$47.7M$224.7M$167.2M
Net income$48.9M-$25.5M$35.6M$186.0M$128.3M
Diluted EPS$0.86-$0.46$0.63$3.24$2.24
Operating cash flow$117.4M$175.4M$113.9M$172.1M$119.0M
Cash and equivalents$566.0M$757.4M$751.3M$523.5M$603.8M
Total assets$2.95B$2.83B$2.83B$2.52B$2.36B
Total liabilities$843.6M$856.9M$866.3M$614.0M$608.3M
Shareholders' equity$2.11B$1.97B$1.96B$1.91B$1.75B

As REPLIGEN CORP tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in RGEN's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 1.01, 2.03, 3.02, 9.01Material agreement · Direct financial obligation · Unregistered sale of equityNov 6, 2026
    EDGAR ↗
  • 8-K · Items 3.02, 8.01, 9.01Unregistered sale of equity · Other eventsOct 30, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsOct 27, 2026
    EDGAR ↗
  • 8-K · Items 2.01, 7.01, 9.01Acquisition or disposition · Reg FD disclosureOct 6, 2026
    EDGAR ↗
  • 8-K · Items 5.02Officer / director changeSep 15, 2026
    EDGAR ↗
  • 8-K · Items 8.01Other eventsSep 8, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsJul 28, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.02, 7.01, 8.01, 9.01Material agreement · Results of operations · Reg FD disclosureJul 22, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 15, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 5, 2026
    EDGAR ↗

About REPLIGEN CORP

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersWALTHAM, MA
IncorporatedDE